Cervical cancer awareness is Jade’s legacy
March 31, 2009Sales and Marketing NHS, vaccines
Jade Goody has left a legacy of hugely increased awareness of cervical cancer in the UK, following her death from …
Patients to get counterfeit warning with each prescription
March 31, 2009Manufacturing and Production counterfeits
New guidance to patients to raise public awareness of fake medicine and its dangers has been launched by the RPSGB …
GSW unveils new pan-European comms service
March 31, 2009Medical Communications GSW
GSW Worldwide, one of the biggest global healthcare advertising agencies has announced the launch of a new pan-European offering. GSW …
Merck hikes investment in Irish biologics plant
March 30, 2009Manufacturing and Production Europe, Ireland
Merck & Co has increased its investment in a new biologic and vaccines facility in Carlow, Ireland, to 220 million …
The 2009 Health Bill
March 27, 20092009, Darzi, NHS, health bill, healthcare
The 2009 Health Bill is the latest major piece of legislation aimed at transforming the NHS, and introduces a range …
CROs under pressure as early-stage pipelines dry up
March 27, 2009Research and Development Pharmsource
There was a sharp slowdown in pharmaceutical outsourcing in the last six months which "really caught a lot of people …
GSK pledges further trial transparency
March 26, 2009Research and Development, Sales and Marketing GSK
GlaxoSmithKline is to make its clinical trials more transparent through a series of moves it believes will facilitate clinical research. …
NICE recommends Pfizer’s Sutent
March 26, 2009Research and Development NICE, Pfizer, Sutent
NICE has issued its final guidance on Pfizer's Sutent, recommending the kidney cancer drug as a first-line treatment. The drug …
GSK linked to Allergan takeover
March 26, 2009Sales and Marketing Allergan, GSK
GlaxoSmithKline may be considering a bid to buy Allergan, the company behind 'cosmaceutical' products such as Botox. Analysts have seized …
Small and flexible: the manufacturing of tomorrow
March 24, 2009Manufacturing and Production biologics
Biopharmaceutical manufacturing is likely to undergo a dramatic change over the next 20 years, with the today's facilities facing dramatic …
GlaxoSmithKline and UCL to develop biologic
March 24, 2009Research and Development GSK
Researchers at University College London are to work with GlaxoSmithKline to develop a new treatment for the rare and often …
Merck Serono sets up biotech fund
March 24, 2009Research and Development Merck Serono, biotech
Merck Serono has set up a venture capital fund to invest in emerging biotech companies working in its core therapy …
Survey adds pressure for re-think on bowel cancer drugs
March 24, 2009Medical Communications, Sales and Marketing Cancer
A new survey by Beating Bowel Cancer has highlighted the problems facing patients with the condition in getting the best …
Biosimilars: time for an approval pathway in the US
March 23, 2009Research and Development, Sales and Marketing US, generics
Congress has received another bill seeking to establish a biosimilars approval pathway in the US. HR 1427 represents the latest …
Bayer strikes R&D deal with Chinese university
March 20, 2009Research and Development Bayer, China, academic research
Bayer has furthered its R&D expansion in China with an agreement to form a joint pharmaceutical research centre with Tsinghua …
Lundbeck launches sleep awareness campaign
March 20, 2009Sales and Marketing Lundbeck, sleep
Lundbeck has launched a campaign aiming to raise awareness of insomnia and sleep problems. 'Sleep well, Live well ' is …
Shire withdraws ADHD patch filing
March 19, 2009Research and Development, Sales and Marketing Shire
Shire has withdrawn the European marketing application for its Attention Deficit Hyperactivity Disorder (ADHD) patch product Daytrana. The product's active …
Sanofi boosted by Multaq vote of approval
March 19, 2009Research and Development, Sales and Marketing FDA, Multaq, Sanofi, US
An FDA committee has recommended Sanofi-Aventis' new atrial fibrillation treatment Multaq, the company's most important late-stage drug. The FDA cardiovascular …
Latest content
